Phillip Chan

CEO & President at CytoSorbents Corporation

Speaker

Dr. Phillip Chan is the Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO). Over the past 16 years, Dr. Chan has led the company through the EU approval and commercialization of its flagship product, CytoSorb, as a novel blood purification therapy to treat cytokine storm and control potentially deadly inflammation seen in life-threatening illnesses in the intensive care unit and cardiac surgery.

Prior to joining CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the $80M NJTC Venture Fund, one of the largest seed and Series A early-stage venture investors in the greater New York region, and a top 1% performing fund for its vintage.

Dr. Chan is also a co-founder and Vice Chairman of Medality Medical, formerly known as Andrew Technologies, a privately-held medical device company pursuing a surgical cure of Type 2 diabetes through removal of deep mesenteric metabolic fat with its FDA-approved lipoplasty system HydraSolve™.

Dr. Chan received board certification in internal medicine, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. He received his MD/PhD from Yale University School of Medicine and his BSc in cell and molecular biology from Cornell University.